Meet the Company

77 0

Approved Raptor Logo with (R) -04042014

 

 

 

 

VITAL SIGNS

NAME: Raptor Pharmaceuticals

HEADQUARTERS: Novato, CA

STOCK PRICE AS OF 10/15/2014: $10.19

52 WEEK RANGE: $7.12-$17.72

MARKET CAPITALIZATION: $639 million

EMPLOYEES: ~125

APPROVED COMPOUNDS: Cysteamine bitartrate delayed-release capsules (PROCYSBI®), FDA- approved in 2013 for treatment of nephropathic cystinosis in adults and children age 6 and older.

Related Post

HD Insights Volume 3 (PDF)

November 1, 2012 0
[pdf-embedder url=”http://huntingtonstudygroup.org/wp-content/uploads/2016/05/vol-3-fall-2012.pdf”]

Meet the Compound: SD-809 (dutetrabenazine)

January 1, 2014 0
Molecular Formula: C19H21D6NO Molecular Weight: 324 g/mol Mechanism of Action: Tetrabenazine reversibly inhibits monoamine re-uptake, which depletes monoamines and reduces…

Research Round-Up

September 1, 2013 0
By: Lise Munsie, PhD In the lab. . . Cepeda and colleagues performed an electrophysiological study of the striatal microcircuit…